NovaVive Inc. Founded in July 2014, NovaVive acquired a state-of-the-art immunotherapeutic platform based on mycobacterium cell wall fraction (MCWF) technology. With regulatory-approved products for cattle, horses, and dogs, NovaVive offers effective solutions to veterinarians in the USA, Canada, Australia, and New Zealand.

One of their key products is Amplimune™, an MCWF-based immunotherapy that provides an alternative to antibiotics for herd health. With the FDA tightening regulations on over-the-counter bovine antibiotics, Amplimune™ offers a prescription-free option for farmers and ranchers. Another innovative offering from NovaVive is Equimune®, a USDA-approved immunotherapeutic for preventing and treating Equine Herpes Virus (EHV-1) in horses.

As EHV-1 outbreaks become more frequent, Equimune® is proving to be a valuable tool in maintaining horse health. Headquartered in Napanee, Ontario, Canada, NovaVive is committed to staying at the forefront of immunobiology research and bringing cutting-edge solutions to the veterinary industry. Stay up-to-date with NovaVive news by signing up for their newsletter on their website